Search results
Results from the WOW.Com Content Network
In contrast to weight loss from inadequate caloric intake, cachexia causes mostly muscle loss instead of fat loss. Diagnosis of cachexia can be difficult due to the lack of well-established diagnostic criteria. Cachexia can improve with treatment of the underlying illness but other treatment approaches have limited benefit.
Unexplained weight loss: Weight loss that is unintended and not explained by diet, exercise or other illness may be a warning sign of many types of cancer Unexplained pain : Pain that persists, has no clear cause, and does not respond to treatment may be a warning sign of many types of cancers.
Cancer-related fatigue is a symptom of fatigue that is experienced by nearly all cancer patients. [1] Among patients receiving cancer treatment other than surgery, it is essentially universal. Fatigue is a normal and expected side effect of most forms of chemotherapy, radiation therapy, and biotherapy. [2]
Once a cancer has metastasized, prognosis normally becomes much worse. About half of patients receiving treatment for invasive cancer (excluding carcinoma in situ and non-melanoma skin cancers) die from that cancer or its treatment. [25] A majority of cancer deaths are due to metastases of the primary tumor. [204]
The clinical relevance of PCCI is significant, considering the increasing number of long-term cancer survivors in the population, many of whom may have been treated with aggressive dosing of chemotherapeutic agents, or with chemotherapy as an adjuvant to other forms of treatment. [7] In some patients, fear of PCCI can impact treatment decisions.
Image credits: Emergency-Economy654 #5. Patient here. I was right about having a pituitary microadenoma causing Cushing’s disease. I asked multiple doctors to help me with various symptoms ...
Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. [1] Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, [2] and PARP inhibitors such as olaparib. [3]
Some patients – particularly those who are terminally ill – may not wish to be involved in making pain management decisions, and may delegate such choices to their treatment providers. The patient's participation in their treatment is a right, not an obligation, and although reduced involvement may result in less-than-optimal pain ...